J. D. de Groot

Metastatic Uveal Melanoma: Treatment Strategies and Survival—Results from the Dutch Melanoma Treatment Registry

C. Blank, G. Hospers, J. Haanen, 2019, Cancers.

Safe Stop IPI-NIVO trial: early discontinuation of nivolumab upon achieving a complete or partial response in patients with irresectable stage III or metastatic melanoma treated with first-line ipilimumab-nivolumab – study protocol

H. Westgeest, A. van den Eertwegh, E. Kapiteijn, 2024, BMC cancer.

Survival outcomes of patients with advanced melanoma from 2013 to 2017: Results of a nationwide population-based registry.

J. Haanen, G. Vreugdenhil, J. D. de Groot, 2020, European journal of cancer.

Improving survival in advanced melanoma patients: a trend analysis from 2013 to 2021

G. Hospers, J. Haanen, A. van den Eertwegh, 2024, EClinicalMedicine.

Multi-omic analysis identifies hypoalbuminemia as independent biomarker of poor outcome upon PD-1 blockade in metastatic melanoma

J. Haanen, V. Retèl, J. van de Haar, 2024, Scientific reports.

BRAF/MEK inhibitor rechallenge in advanced melanoma patients

G. Hospers, J. Haanen, A. van den Eertwegh, 2024, Cancer.

Neoadjuvant Nivolumab and Ipilimumab in Resectable Stage III Melanoma.

P. Ascierto, G. Hospers, J. Haanen, 2024, The New England journal of medicine.